Willis Towers Watson Public Limited Company will report second-quarter 2019 results on Jul 31 after market close. The company delivered positive earnings surprise in two of the last four quarters with the average beat being 4.73%.
Let’s see how things are shaping up for this announcement.
Willis Towers’ second-quarter results are likely to benefit from higher organic commissions and fees, solid customer retention levels, growth in new business and strong exchange business.
Commissions and fees are expected to benefit from organic growth across segments and rich contribution from acquisitions as well as geographic diversification.
Human Capital & Benefits, the largest segment of the company, should continue to benefit from new businesses. This should drive North America revenues and global benefit management appointments. The Zacks Consensus Estimate for segment revenues is pegged at $810 million, indicating an upside of 3.8% from the year-ago reported figure.
Corporate Risk & Broking segment’s revenues should benefit from new business. The Zacks Consensus Estimate for segment revenues is pegged at $685 million, implying an increase of 1.6% from the year-ago reported figure.
Investment, Risk & Reinsurance segment’s revenues are likely to benefit from new business and favorable renewals. The Zacks Consensus Estimate for segment revenues is pegged at $395 million, up 2.6% year over year.
Continued enrolment and a robust sales pipeline are expected to drive exchange business.
Expenses are likely to weigh on margin expansion.
The Zacks Consensus Estimate for earnings per share is pegged at $1.76, suggesting 3.5% year-over-year increase on 3.1% higher revenues.
What Our Quantitative Model States
Our proven model shows that Willis Towers is likely to beat on earnings in the to-be-reported. This is because the stock has both a positive Earnings ESP and a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen.
Earnings ESP: Willis Towers has an Earnings ESP of +0.28%. This is because the Most Accurate Estimate of $1.77 is higher than the Zacks Consensus Estimate of $1.76. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Willis Towers Watson Public Limited Company Price and EPS Surprise
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Willis Towers Watson Public Limited Company will report second-quarter 2019 results on Jul 31 after market close. The company delivered positive earnings surprise in two of the last four quarters with the average beat being 4.73%.
Let’s see how things are shaping up for this announcement.
Willis Towers’ second-quarter results are likely to benefit from higher organic commissions and fees, solid customer retention levels, growth in new business and strong exchange business.
Commissions and fees are expected to benefit from organic growth across segments and rich contribution from acquisitions as well as geographic diversification.
Human Capital & Benefits, the largest segment of the company, should continue to benefit from new businesses. This should drive North America revenues and global benefit management appointments. The Zacks Consensus Estimate for segment revenues is pegged at $810 million, indicating an upside of 3.8% from the year-ago reported figure.
Corporate Risk & Broking segment’s revenues should benefit from new business. The Zacks Consensus Estimate for segment revenues is pegged at $685 million, implying an increase of 1.6% from the year-ago reported figure.
Investment, Risk & Reinsurance segment’s revenues are likely to benefit from new business and favorable renewals. The Zacks Consensus Estimate for segment revenues is pegged at $395 million, up 2.6% year over year.
Continued enrolment and a robust sales pipeline are expected to drive exchange business.
Expenses are likely to weigh on margin expansion.
The Zacks Consensus Estimate for earnings per share is pegged at $1.76, suggesting 3.5% year-over-year increase on 3.1% higher revenues.
What Our Quantitative Model States
Our proven model shows that Willis Towers is likely to beat on earnings in the to-be-reported. This is because the stock has both a positive Earnings ESP and a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen.
Earnings ESP: Willis Towers has an Earnings ESP of +0.28%. This is because the Most Accurate Estimate of $1.77 is higher than the Zacks Consensus Estimate of $1.76. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Willis Towers Watson Public Limited Company Price and EPS Surprise
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on HIG - FREE
Get the latest research report on MMC - FREE
Get the latest research report on RDN - FREE